Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
09 August, 2020 02:09 IST
Aurobindo Pharma receives EIR for Hyderabad unit
Source: IRIS | 19 Feb, 2020, 05.39PM
Comments  |  Post Comment

Aurobindo Pharma, a mid-size pharmaceutical company, notified the stock exchanges that it had received an establishment inspection report (EIR) from the US drug regulator (USFDA) for Hyderabad unit.

It said ''the company has received EIR with voluntary action initiated (VAI) status from the United States Food and Drug Administration (USFDA).''

In November, USFDA inspected Unit IV, a general injectable formulation manufacturing facility at Pashamylaram in Hyderabad and had issued 'Form 483' with 14 observations.

Shares of the company gained Rs 102.05, or 20.4%, to settle at Rs 602.25. The total volume of shares traded was 897,415 at the BSE (Wednesday).



Aurobindo Pharma Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer